Navigation Links
Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
Date:5/30/2008

Post-hoc analysis of pivotal studies presented at the National Lipid

Association's Annual Scientific Sessions

PARSIPPANY, N.J., May 30 /PRNewswire/ -- Daiichi Sankyo, Inc., announced today that data from post-hoc analyses of three pivotal studies demonstrated that the addition of Welchol(TM), (colesevelam HCl) to common diabetes treatment regimens can lower A1C in patients with type 2 diabetes mellitus by 1% or greater. The analyses included all patients receiving Welchol in these studies (n=512). Almost half (47%) of the patients in the analyses had a mean reduction in A1C of 1.04% and nearly a quarter (24%) had a mean reduction as great as 1.40%. Type 2 diabetes can put people at risk for serious health complications such as blindness, amputation and kidney failure.(1)

A second post-hoc analysis demonstrated that Welchol lowered A1C and LDL-cholesterol (LDL-C) levels consistently across type 2 diabetes patients, regardless of age, gender or race. These findings were included among five poster presentations by Daiichi Sankyo at the National Lipid Association (NLA) Annual Scientific Sessions.

The American Diabetes Association (ADA) recommends that people with type 2 diabetes control both blood glucose and cholesterol levels to reduce the risk of developing cardiovascular disease.(2) The National Cholesterol Education Program (NCEP) recommends that patients with type 2 diabetes keep their cholesterol levels in check and target an LDL-C goal of <100 mg/dL.(3) Despite this recommendation, nearly 40 percent of patients with type 2 diabetes have LDL-cholesterol levels greater than 130 mg/dL.(4) Welchol is the first and only therapy approved to treat both type 2 diabetes and high LDL-cholesterol.

"These findings are significant given the critical importance of achieving and maintaining A1C control," said Vivian A. Fonseca, Professor of Medicine and Pharmacology and Chief, Section of Endocrinology, Tulane University He
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
2. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
3. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
4. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
7. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
8. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
11. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... N.Y., Feb. 21, 2012  Regeneron Pharmaceuticals, Inc. (Nasdaq: ... following investor conferences: , Citi 2012 Global Healthcare ... 28, 2012 , RBC Capital Markets, Healthcare Conference ... 2012 The sessions may be accessed through ...
... PHILADELPHIA, Pennsylvania and WALTHAM, Massachusetts, February 21, 2012 ... clinical decision support content and analytics tools into ... Elsevier , a world-leading provider of scientific, ... PatientKeeper ®, the leading provider of physician ...
Cached Medicine Technology:Regeneron Announces February 2012 Investor Conference Presentations 2Elsevier Integrates its Clinical Decision Support Solutions Into PatientKeeper CPOE 2Elsevier Integrates its Clinical Decision Support Solutions Into PatientKeeper CPOE 3Elsevier Integrates its Clinical Decision Support Solutions Into PatientKeeper CPOE 4
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
(Date:4/17/2014)... An international team led by researchers at UC ... which plays a key role in cell division, also ... is the first time the complex has been shown ... cyclin B1/Cdk1 an excellent target to control cellular energy ... research was published online today in the journal ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... more accurate in early tests , , WEDNESDAY, Feb. 18 ... the widely used anticoagulant warfarin safer by predicting the ... U.S. Food and Drug Administration estimates that 2 million ... that can cause strokes. Reasons range from implantation of ...
... Products for Pregnant Women Creates a Buzz in Hollywood--WESTPORT, ... full-swing, Beaute de Maman , a unique line ... the pregnant woman by an obstetrician, has made it ... Penelope Ann Miller, Salli Richardson-Whitfield ( "Eureka" ), Chyler ...
... /PRNewswire-FirstCall/ - The Westaim Corporation announced today that for the year ... million, or 11 cents per share, on revenues of $22.4 million ... per share, on revenues of $31.8 million in the previous year. ... a net income of $2.7 million, or 3 cents per share, ...
... women had no survival advantage over others , , ... smoke have higher death rates than low-paid nonsmokers of ... conclude that smoking may be a greater cause of ... found that smoking cancels out the survival advantage women ...
... New research finds misdiagnosis risk goes up as age goes ... boy complaining of numbness at a Detroit emergency room was ... A 24-year-old woman with sharp pain in her left eye ... by ER doctors that she had a migraine. , And ...
... St. Luke,s Medical Center Discovers Way to Fight ... 18 Researchers at Aurora St. Luke,s Medical ... unusual, but serious, side effect from natalizumab (Tysabri(R)), ... effect is a brain virus called progressive multifocal ...
Cached Medicine News:Health News:Genetics May Help Fine-Tune Warfarin Dosage 2Health News:Genetics May Help Fine-Tune Warfarin Dosage 3Health News:Genetics May Help Fine-Tune Warfarin Dosage 4Health News:Hollywood's Celebrity Moms-To-Be Get Acquainted With All-Natural Beaute de Maman Product Line 2Health News:Hollywood's Celebrity Moms-To-Be Get Acquainted With All-Natural Beaute de Maman Product Line 3Health News:Westaim announces 2008 year-end results 2Health News:Westaim announces 2008 year-end results 3Health News:Westaim announces 2008 year-end results 4Health News:Westaim announces 2008 year-end results 5Health News:Westaim announces 2008 year-end results 6Health News:Westaim announces 2008 year-end results 7Health News:Westaim announces 2008 year-end results 8Health News:Westaim announces 2008 year-end results 9Health News:Westaim announces 2008 year-end results 10Health News:Westaim announces 2008 year-end results 11Health News:Westaim announces 2008 year-end results 12Health News:Social Class, Gender Won't Shield Smokers from Harm 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 2Health News:ER Less Likely to Diagnose Stroke in Younger Folks 3Health News:Research Brings New Hope to Multiple Sclerosis Patients 2
... German Craftsmanship have produced the ... world. Ocutek® now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
1mm by 7mm horizontal punch. Flat serrated handle. Overall length 87mm....
... integrated neck. Piston assembly fits into ... spring to recoil back to ready ... into precision milled cavity in platform. ... - 9.0mm. Designed for the preparation ...
Medicine Products: